AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

Maryland-based biotech NextCure is looking for partners to advance a candidate for the currently incurable rare disease ...

NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...